| Similar Articles |
|---|
 |
The Motley Fool
May 2, 2011
Brian Orelli |
StemCells Up for All the Right Reasons Federal funding doesn't matter for most stem cell companies.   |
The Motley Fool
November 28, 2007
Brian Orelli |
Stem Your Expectations of Stem-Cell Discoveries Making "stem" cells out of skin cells isn't all it's cracked up to be. The recent discovery has a long way to go before it can catch up to the research currently being done with stem cells. |
The Motley Fool
August 31, 2007
Brian Orelli |
A Stem-Cell Primer Public funding from states could help companies doing stem cell research. Read about Geron, StemCells, Osiris Therapeutics, ViaCell and Invitrogen, companies that may profit from the increased public spending. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
The Motley Fool
September 29, 2010
Brian Orelli |
Careful What You Wish For, Stem Cell Investors Investors seem to have forgotten about fundamentals. |
The Motley Fool
October 3, 2007
Brian Orelli |
Big Pharma Loves Your Liver Three big pharma companies, AstraZeneca, GlaxoSmithKline, and Roche, are funding a stem-cell consortium. Investors, take note. |
The Motley Fool
November 14, 2008
Brian Orelli |
Pfizer Takes the Plunge Into Stem-Cell Research The world's largest drugmaker by market cap announced today that it's forming a unit to focus on stem cells. |
The Motley Fool
December 22, 2009
Brian Orelli |
Pfizer Swings for the Fences A long shot, but at least it's cheap. Pfizer seems to have taken a particular liking to stem cells, having established a unit to study them last year |
BusinessWeek
September 23, 2010
Rob Waters |
Stem Cells That Save Big Pharma a Bundle Drugmakers hope to save big by using stem cells to test drugs for dangerous side effects long before costly human trials are needed. |
The Motley Fool
August 27, 2007
Brian Orelli |
Repairing a Broken Heart Stem cells may be the new cure. If research continues on track, Geron expects to ask FDA to start clinical trials late next year or in early 2009. Investors, take note. |
The Motley Fool
July 26, 2004
Brian Gorman |
Stem Cell Researcher a Risk Geron could benefit from a new U.S. president, but in the end, studies of embryonic stem cells may or may not yield breakthroughs, so buying their stock now would be a gamble. |
The Motley Fool
April 14, 2008
Brian Orelli |
Stem Cells Show Off The FDA moves closer to setting up stem cell clinical trials, setting guidelines that put treatment safety first and foremost. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
The Motley Fool
February 2, 2005
Rich Duprey |
Aastrom to Leap Into Trials The biotech firm advances to the next stage of clinical studies in stem cell research. Investors, take note. |
The Motley Fool
October 12, 2010
Travis Hoium |
Geron Shares Popped: What You Need to Know Geron shares jumped 10% after the company announced that its first patient has enrolled in the company's stem cell clinical trial. |
The Motley Fool
November 9, 2004
Charly Travers |
Are Stem Cells a Rule Breaker? Does the science offer real hope or just hype? Biotech investors take on enough risk in the normal course of drug development that they do not need to worry about whether or not the underlying technology even works. |
Pharmaceutical Executive
October 1, 2012
Ben Comer |
Stem Cells: A Promise Deferred? Ideology, politics, and a stilted political debate may be causing pharma to overlook the potential of emerging stem cell therapies in fostering a new generation of cures. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
A Boost for Broken Hearts? The Institute of Regenerative Medicine in Barbados is convinced that stem cells from fetuses can repair cardiac damage. |
BusinessWeek
January 10, 2005
Bruce Einhorn |
Asia Is Stem Cell Central Singapore isn't the only country in the region trying to profit from the U.S. restrictions. Australia, China, India, Japan, and South Korea all see stem cell research as a way to get ahead in biotech. |
| AskMen.com |
Synthetic Sperm Created British scientists claimed Wednesday to have created human sperm from stem cells, but other experts questioned their data. |
The Motley Fool
July 14, 2011
Rich Smith |
What's All the Fuss About Stem Cells? Stocks are up on news of Sweden's miracle meatball. Over the weekend, Swedish researchers announced the successful transplant of an artificial trachea to a patient whose own organ had been ravaged by cancer. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
BusinessWeek
July 26, 2004
Arlene Weintraub |
The Stem-Cell Flap: Simmer Down Advocates are overstating stem cells' near-term ability to treat grave illnesses. In doing so, they not only distort the science; the hopes they raise among many people who are sick today are also sure to be dashed. |
Scientific American
December 2008
Tim Hornyak |
Turning Back the Cellular Clock: A Farewell to Embryonic Stem Cells? Shinya Yamanaka discovered how to revert adult cells to an embryonic state. These induced pluripotent stem cells might soon supplant their embryonic cousins in therapeutic promise |
Salon.com
December 29, 2000
Arthur Allen |
Will Thompson, Bush clash over human embryo research? The HHS nominee supports it, but right-to-lifers want it stopped.... |
The Motley Fool
May 3, 2005
Charly Travers |
Is Geron a Rule Breaker? At the forefront of stem cell research, can the company live up to its lofty potential? Geron's science is hot. Its stock is not. |
Bio-IT World
Dec 2005/Jan 2006
Maureen McDonough |
The Century of the Cell Like most new life science industries, the stem cell business landscape looks like a maze. There are many paths, turns, and dead-ends, but it is quite possible that there will be more than one route to the finish line. |
The Motley Fool
August 2, 2010
Brian Orelli |
Back in Love With Geron Investors' love / hate relationship with Geron is back in the worship phase, with the stem cells company up 17% on Friday and nearly an additional 10% or so today. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Want To Bank Your Own Stem Cells? One Los Angeles startup believes everyone should, to be ready when regenerative therapies start hitting the market |
The Motley Fool
June 21, 2005
Brian Gorman |
Stem Cell Chatter Despite the promise suggested by early studies, embryonic stem cell research remains highly speculative. More concrete results, not the amount of cash being poured into research, are the best basis for investing decisions. |
The Motley Fool
May 15, 2007
Mike Havrilla |
Secret Cytori Cytori may be a lesser-known player in the stem-cell therapy field, but it's a stock to watch in the coming year. |
Bio-IT World
August 2005
Maureen McDonough |
U.K. Framework Offers Stem Cells a Future The United Kingdom has managed to cut through the noise surrounding stem cell research, creating a regulatory framework that fosters an environment of international collaboration and excellent R&D programs. And they try to do it all in an ethical way. |
The Motley Fool
January 20, 2012
Dan Caplinger |
Can Geron Recover in 2012? Let's look at this year's prospects for this company. |
BusinessWeek
May 24, 2004
Arlene Weintraub |
Repairing The Engines Of Life Can research into stem cells and other advanced techniques heal ailing hearts and brains? U.S. labs are hamstrung by the federal government. |
Bio-IT World
April 2006 |
Virtual Stem Cell Laboratory Goes Live Children's Hospital in Boston's Virtual Stem Cell Laboratory web site allows online visitors to manipulate and investigate a "living" culture of embryonic stem cells. |
The Motley Fool
August 19, 2010
Brian Orelli |
The Mice Can Walk! Remember you're essentially buying a lottery ticket investing in this or any other unproven early stage biomedical technology. |
BusinessWeek
July 18, 2005 |
Research and "False Expectations" While Korean scientist Hwang Woo Suk is eager to see practical applications of his work, he warns that optimism needs to be qualified by reality. |
The Motley Fool
August 24, 2007
Brian Orelli |
Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it. |
Chemistry World
April 6, 2009
Rebecca Trager |
US funding boost - a threat to EU science? These developments have raised some concern about the possibility of a 'brain drain' from Europe to the US, as these falling barriers have quickly made the region a more appealing destination for researchers. |
Inc.
February 2005
Patrick J. Sauer |
The State of Stem Cell Research Californians are hoping that stem cell research will do for them what the invention of the car did for Michigan. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Europe approves stem cell therapy A stem cell treatment for severe cornea damage has been granted conditional approval by the European commission. |
Fast Company
March 2008
Elizabeth Svoboda |
Eureka? Alan Trounson, the new president of California's stem-cell agency, talks about the science, the opposition, and his qualms about working with embryos. |
HHMI Bulletin
May 2010
Sarah C.P. Williams |
Lab-Grown Liver New cell culture system solves problem of growing liver cells. |
Reason
July 2005
Ronald Bailey |
Censored Science Speaking out on stem cells: The Washington Post noted that even President Bush's handpicked NIH director, Elias Zerhouni, may not be on board with administration's stem cell policy. |
Fast Company
March 2009
Tim McKeough |
Banking Stem Cells For Future Use A personal banking system for stem cells. |
Reactive Reports
Issue 64
David Bradley |
Stem to Sperm New research shows that stem cells from human bone marrow can be converted into early-stage sperm. The discovery could lead to novel fertility treatments in the long-term. |
Bio-IT World
July 15, 2003
Kevin Davies |
Stem Cell Suicide The International Society for Stem Cell Research must engage in a political discourse to salvage the hope of embryonic stem cell research. |
BusinessWeek
January 23, 2006
Arlene Weintraub |
A "Body Blow" To Stem Cell Research Funding for stem cell research in the U.S. wasn't so hot even before the Korean scandal broke. |
Wired
January 2003
Charles C. Mann |
The First Cloning Superpower Inside China's race to become the clone capital of the world. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
